NEW YORK, NY / ACCESSWIRE / September 16, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

TGTX Shareholders Click Here: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=31860&wire=1 WEBR Shareholders Click Here: https://www.zlk.com/pslra-1/weber-inc-information-request-form?prid=31860&wire=1 LFST Shareholders Click Here: https://www.zlk.com/pslra-1/lifestance-health-lawsuit-loss-submission-form?prid=31860&wire=1

TGTX Lawsuit on behalf of: investors who purchased January 15, 2020 - May 31, 2022 Lead Plaintiff Deadline : September 16, 2022 TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=31860&wire=1

According to the filed complaint, during the class period, TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Weber Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's August 2021 initial public offering. Lead Plaintiff Deadline : September 27, 2022 TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/weber-inc-information-request-form?prid=31860&wire=1

According to the filed complaint, (1) Weber was reasonably likely to implement price increases; (2) as a result, consumer demand for Weber's products was reasonably likely to decrease; (3) due to the resulting inventory buildup, Weber was reasonably likely to run promotions to "enhance retail sell through"; (4) the foregoing would adversely impact Weber's financial results; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

LifeStance Health Group, Inc. LFST

This lawsuit is on behalf of all purchasers of LifeStance common stock pursuant and/or traceable to the documents issued in connection with LifeStance's June 10, 2021 initial public stock offering. Lead Plaintiff Deadline : October 11, 2022 TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/lifestance-health-lawsuit-loss-submission-form?prid=31860&wire=1

According to the filed complaint, (i) the number of virtual visits clients were undertaking utilizing LifeStance Health was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining LifeStance Health's out-patient/virtual revenue growth; (ii) the percentage of in-person visits clients were undertaking utilizing LifeStance Health was increasing as the COVID-19 lockdowns were being lifted, thereby causing LifeStance Health's operating expenses to increase substantially; (iii) LifeStance Health had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the initial public offering's registration statement, and LifeStance Health had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (iv) as a result, LifeStance Health's business metrics and financial prospects were not as strong as the initial public offering's registration statement represented.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP Joseph E. Levi, Esq. Eduard Korsinsky, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171 www.zlk.com

SOURCE: Levi & Korsinsky, LLP

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.